

NOTICE: This is a translation of a notice in Japanese issued on June 27, 2023 and is made solely for the convenience of foreign shareholders. In case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

Securities code: 4536
June 27, 2023

**RESOLUTION NOTICE
OF THE 111TH ANNUAL GENERAL MEETING OF SHAREHOLDERS
OF SANTEN PHARMACEUTICAL CO., LTD.**

Dear Shareholder:

We hereby inform you of the reports and the resolutions that were made, as set forth below, at the 111th Annual General Meeting of Shareholders of the Company that was held today.

Yours very truly,

Takeshi Ito
Representative Director, President & CEO
SANTEN PHARMACEUTICAL CO., LTD.
4-20, Ofuka-cho, Kita-ku, Osaka, Japan

Reports:

1. Report on the Business Report, Consolidated Financial Statements and Financial Statements for the 111th Business Term (April 1, 2022 to March 31, 2023)
2. Report on the Audit Reports of the Accounting Auditors and the Board of Corporate Auditors on the Consolidated Financial Statements for the 111th Business Term (April 1, 2022 to March 31, 2023)

As regards the items set forth above, the contents thereof were reported.

Resolved Items:**Proposal No. 1: Appropriation of Surplus**

As to this item, the term-end dividends of profits were resolved to be JPY 16 per share as per the original proposal. Consequently, the total dividends for the annual business term, including the interim dividends previously distributed, are at JPY 32 per share.

Proposal No. 2: Appointment of Seven (7) Directors

As regards this item, Akira Kurokawa, Takeshi Ito, Kanoko Oishi, Yutaro Shintaku, Kunihiro Minakawa, Noboru Kotani and Tamie Minami were appointed as per the original proposal; each of them assumed his or her office. Kanoko Oishi, Yutaro Shintaku, Kunihiro Minakawa, Noboru Kotani and Tamie Minami are Outside Directors.

Proposal No. 3: Appointment of Two (2) Corporate Auditors

As regards this item, Junichi Asatani and Yaeko Hodaka were appointed as per the original proposal; each of them assumed his or her office. Junichi Asatani and Yaeko Hodaka are Outside Corporate Auditors.

ANNOUNCEMENT

At the Board of Directors' meeting, which was held after the close of this Annual General Meeting of Shareholders, Akira Kurokawa was appointed as Representative Director, Chairman, and Takeshi Ito was appointed as Representative Director, President and CEO. Each of them assumed the said office.

As a result thereof, the Directors and Corporate Auditors of the Company shall be as follows:

Directors and Corporate Auditors

Akira Kurokawa	Representative Director Chairman
Takeshi Ito	Representative Director President, Chief Executive Officer (CEO)
Kanoko Oishi*	Director
Yutaro Shintaku*	Director
Kunihito Minakawa*	Director
Noboru Kotani*	Director
Tamie Minami*	Director
Hiroshi Isaka	Standing Corporate Auditor
Masahiko Ikaga**	Corporate Auditor
Junichi Asatani**	Corporate Auditor
Yaeko Hodaka**	Corporate Auditor

* The Outside Directors (indicated by an asterisk (*) next to their names) are Independent Officers (as set forth in Article 436-2, Paragraph 1 of the Securities Listing Regulations of the Tokyo Stock Exchange, Inc.; hereinafter, the same classification shall apply).

** The Outside Corporate Auditors (indicated by two asterisks (**) next to their names) are Independent Officers.

End.